Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

INTRODUCTION: S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advanced squamous lung carcinoma (sq non-small-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Leighl, Natasha B, Redman, Mary W, Rizvi, Naiyer, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Wade, James L, Irvin, William J, Reddy, Sreekanth C, Crawford, Jeffrey, Bradley, Jeffrey D, Stinchcombe, Thomas E, Ramalingam, Suresh S, Miao, Jieling, Minichiello, Katherine, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386207/
https://www.ncbi.nlm.nih.gov/pubmed/34429332
http://dx.doi.org/10.1136/jitc-2021-002973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386207/
https://www.ncbi.nlm.nih.gov/pubmed/34429332
http://dx.doi.org/10.1136/jitc-2021-002973

Ejemplares similares